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ABSTRACT
Background. The Kidney Disease: Improving Global
Outcomes guidelines have cautioned against administering in-
travenous (IV) iron to hemodialysis patients with high serum
ferritin levels due to safety concerns, but prior research has
shown that the association between high ferritin and mortality
could be attributed to confounding by malnutrition and inﬂam-
mation. Our goal was to better understand the ferritin–
mortality association and relative inﬂuence of IV iron and
inﬂammation in the USA, where ferritin levels have recently in-
creased dramatically, and in Europe and Japan, where ferritin
levels are lower and anemia management practices differ.
Methods. Data from 18 261 patients in Phases 4 and 5 (2009–
15) of the international Dialysis Outcomes and Practice
Patterns Study, a prospective cohort study, were analyzed.
Using Cox regression, we modeled the association
between baseline ferritin and 1-year mortality with restricted
cubic splines and assessed the impact of potential confounders.
Results.Median ferritin levels were 718 ng/mL in the USA, 405
in Europe and 83 in Japan. High ferritin levels were associated
with elevated mortality (relative to region-speciﬁc medians) in
all three regions. The strength of this association was attenuated
more by adjustment for malnutrition and inﬂammation than by
IV iron and erythropoiesis-stimulating agent dose in each
region.
Conclusion. The utility of high ferritin as a biomarker for clini-
cal risk due to excess iron stores may be limited, although cau-
tion regarding IV iron dosing to higher upper ferritin targets
remains warranted. Research to resolve biomarker criteria for
iron dosing, and whether optimal anemia management strate-
gies differ internationally, is still needed.
Keywords: anemia, ferritin, hemodialysis, inﬂammation, iron,
mortality
INTRODUCTION
Most hemodialysis (HD) patients require treatment with
erythropoiesis-stimulating agents (ESAs) and/or intravenous
(IV) iron to maintain hemoglobin levels within target ranges
[1, 2]. Striking the right balance of ESAs and IV iron use in the
context of safety concerns continues to generate extensive dis-
cussion in the nephrology community [3–6]. Large cohort stud-
ies investigating the association between IV iron dosing and
adverse events in HD patients have yielded mixed results [7–
11]. Higher mortality risk with larger doses of IV iron was
observed by Bailie et al. [7] (300mg/month) and Kalantar-
Zadeh et al. [8] (>400mg/month). In contrast, no association
between IV iron dose and all-cause mortality was observed by
Miskulin et al. [9] and Feldman et al. [10]. Serum ferritin is one
marker of iron stores, along with transferrin saturation (TSAT),
commonly used to guide IV iron dosing practices in dialysis.
However, the value of using high ferritin levels to limit IV iron
dosing due to safety concerns is uncertain.
A recent study of dialysis patients, excluding those with
overt inflammation or malnutrition, found that ferritin was the
best marker of iron stores based on hepatic magnetic resonance
imaging and recommended that target values should be lowered
to avoid iron overload [12]. However, others have argued that
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ferritin has several disadvantages as an index of iron status and
is inadequate for guiding iron repletion therapy [13–17]. Serum
ferritin is elevated when patients are inflamed, leading to strong
correlations with C-reactive protein (CRP) and other markers
of acute illness, such as recent hospitalization [18–21]. The util-
ity of a single measurement of serum ferritin as a marker of iron
stores may be further limited by extreme within-patient vari-
ability over time [22–23]. These issues complicate attempts to
interpret studies seeking to estimate the effect of ferritin on ad-
verse events.
Bazeley et al. [21] reported that serum ferritin, in contrast to
CRP and serum albumin, did not improve the prediction of
mortality risk beyond that of other markers of inflammation.
Kalantar-Zadeh et al. [8] showed that while high ferritin levels
were strongly associated with elevated mortality in a crude
analysis, this association was almost eliminated after adjust-
ment for patient characteristics and malnutrition–inflamma-
tion complex syndrome. Since the analysis of this 2001–03
cohort [8], ferritin levels have increased dramatically among US
HD patients [24–26], largely driven by acceptance of higher fer-
ritin and/or TSAT targets at many centers following the intro-
duction of the Centers for Medicare & Medicaid Services
bundled payment system in 2011 [27]. In the current setting, a
large proportion of US patients have serum ferritin levels
>800 ng/mL [24, 25]. These levels far exceed 2012 guidelines
[2] released by the Kidney Disease: Improving Global
Outcomes (KDIGO) Anemia Work Group (which recom-
mended stopping IV iron dosing when ferritin is >500 ng/mL)
and a 2013 response from the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (KDOQI) recom-
mending IV iron treatment when ferritin is<800 ng/mL [28].
A reassessment of the potential risk of high ferritin levels is
warranted for two reasons: (i) the safety of the very high ferritin
levels observed in the USA in the postbundle [27] era is un-
known, as anemia management practices may plausibly drive
the ferritin–mortality relation, in addition to inflammation and
(ii) a comparison of the ferritin–mortality association in the
USA versus Europe and Japan, where differing anemia manage-
ment practices, financial incentives and/or guidelines [29–31]
keep ferritin levels much lower than in the USA [32–34], could
provide further clarification of the mechanism(s) behind the
ferritin–mortality association in different international settings.
Our primary objectives were to characterize the association be-
tween high ferritin levels and mortality in three international
regions and to assess the impact of potential confounders,
namely IV iron dosing and inflammation, on that association.
MATERIALS AND METHODS
Data source
The Dialysis Outcomes and Practice Patterns Study (DOPPS)
is a large international prospective cohort study of patients
18 years of age treated with in-center HD (see http://www.
dopps.org for details). Patients were randomly selected from na-
tional samples of dialysis facilities in each country [35, 36]. Study
approval and patient consent were obtained as required by na-
tional and local ethics committee regulations. In this analysis,
patient data from nine countries in three regions were used: the
USA, Europe (Belgium, France, Germany, Italy, Spain, Sweden,
UK) and Japan. Data on demographics (baseline), comorbid con-
ditions (baseline), laboratory values (monthly) and prescriptions
(monthly) were abstracted from medical records using uniform
and standardized data collection tools. Transfusion data were not
collected prior to 2011, and not at all in most US facilities; CRP
was not routinely measured in US facilities.
The primary analysis of ferritin and mortality included
patients in DOPPS Phase 4 (2009–11) and Phase 5 (2012–15).
The exposure of interest was each patient’s first serum ferritin
measured >4months after study entry, allowing for a 3- to 4-
month window to collect information on potential confounders
(e.g. IV iron and ESA dose) prior to baseline ferritin measure-
ment. For the outcome of all-cause mortality, follow-up started
at baseline ferritin measurement and continued for 1 year or un-
til death, study phase end, loss to follow-up, transplantation,
switch to home dialysis or 7 days after leaving the facility
(whichever occurred first). Figure 1 summarizes the timing of
data collection for variables included in the Cox models. The
number of patients in our primary analysis was 8510 in the
USA, 6757 in Europe and 2994 in Japan. A separate analysis of
facility ferritin targets used a question from the annual (2009–
14) DOPPS Medical Director Survey: ‘For clinical
protocols relating to serum ferritin at your unit, indicate the cur-
rent upper limit of target used for patients in your dialysis unit’.
Statistical analysis
We summarized patient characteristics by region-specific
ferritin categories. To estimate the association between ferritin
and all-cause mortality in each region, we used Cox regression
stratified by calendar year and by dialysis organization size in
the USA or by country in Europe. We accounted for facility
clustering using robust sandwich covariance estimators.
Anticipating a nonlinear association with mortality, serum fer-
ritin was parameterized using a restricted cubic spline with
three knots at the 10th, 50th and 90th percentiles within each
region [37], treating region-specific medians as reference levels.
Results outside of cohort-specific 5th and 95th percentiles were
suppressed to limit tenuous extrapolation. To avoid cluttering
the figures with several sets of confidence intervals (CIs), the
precision of the hazard ratio (HR) estimates from these models
are presented as 95% CIs at selected ferritin levels in Table 1.
The proportional hazards assumption was confirmed via log-
log survival plots and by testing the interaction between log-
time and ferritin in each region.
To investigate the degree to which the unadjusted associa-
tion between high ferritin and mortality could be attributed to
certain mortality risk factors associated with ferritin level (e.g.
IV iron dose, inflammatory markers) in each region, we used a
series of five progressively adjusted models to observe changes
in the shape and magnitude of the ferritin–mortality associa-
tion, as described in Figures 3A–C. The adjustments were as fol-
lows: Model 1 (case mix): age, sex, black race, vintage, 13
comorbidities (listed in Table 2), catheter use, and Kt/V at study
entry; Model 2 (anemia factors): Model 1 plus hemoglobin, av-
erage IV iron and ESA dose prescribed during the 3–4months
2 A. Karaboyas et al.Downloaded from https://academic.oup.com/ndt/advance-article-abstract/doi/10.1093/ndt/gfy190/5052242
by Ghent University user
on 23 July 2018
prior to ferritin measurement, an interaction between IV iron
dose and vintage and an indicator for whether the patient re-
ceived a bolus IV iron dose, defined as at least 1 of the 3–4 prior
months with at least 500mg IV iron; Model 3 (nutrition and in-
flammation): Model 2 plus body mass index (BMI) and nor-
malized protein catabolic rate (nPCR) at study entry, any
hospitalization during the prior 3–4months, albumin, creati-
nine, white blood cell (WBC) count, potassium, bicarbonate,
phosphorus and phosphorus squared; Model 4: Model 3 plus
CRP (not measured routinely in the US); Model 5: Model 4 plus
an indicator for any blood transfusion in the prior 3–4months
(only limited data collected in the USA). Progressive model
adjustments are sensitive to the order in which covariates are
added; since we hypothesized that the crude association be-
tween high ferritin and mortality is principally explained by in-
flammation rather than anemia measures and treatments, we
added anemia management variables first to provide a more
conservative estimate of the impact of inflammation. In analy-
ses of Japanese patients, covariates with near-uniform distribu-
tions (race, catheter use) or high missingness (serum
bicarbonate) were excluded from the model.
To deal with missing covariate data, we used multiple impu-
tation, assuming data were missing at random.Missing covariate
values were multiply imputed using the Sequential Regression
Multiple Imputation Method by IVEware [38]. Results from 20
such imputed data sets were combined for the final analysis us-
ing Rubin’s formula [39]. The proportion of missing data was
<20% for all variables used for covariate adjustment, with the
exception of blood transfusions (52% in Europe, 43% in Japan),
nPCR (33% in Europe), Kt/V (33% in Europe), CRP (27% in
Japan, 21% in Europe) and serum bicarbonate (26% in Europe).
A full summary of missing data is provided in Supplementary
data, Table S1. All analyses were conducted using SAS software,
version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Distribution of ferritin levels by region
Median ferritin levels were 718 ng/mL [interquartile range
(IQR) 439–1026)] in the USA, 405 (224–640) in Europe and 83
(36–176) in Japan. Since these levels were markedly different by
FIGURE 1: Timing of variables included in models. aExcluded in Japan due to near-uniform distributions (black race, catheter use) or high
missingness (bicarbonate). bHemoglobin measured at the beginning and end of the interval. cBlood transfusions and CRP excluded in USA
due to limited data collection. RBC, red blood cell.
Table 1. Ferritin and mortality, by region and level of adjustment
HR (95% CI) of ferritin (ng/mL)
Region 20 100 200 400 700 1000 1400
USA (Ref ¼ 718 ng/mL)
Model 1 – – 0.92 (0.77–1.09) 0.94 (0.85–1.04) 1.00 (0.99–1.00) 1.10 (1.05–1.14) 1.29 (1.19–1.40)
Model 2 – – 0.87 (0.73–1.04) 0.92 (0.83–1.01) 0.99 (0.99–1.00) 1.09 (1.05–1.13) 1.24 (1.14–1.35)
Model 3 – – 0.83 (0.68–1.01) 0.89 (0.80–1.00) 0.99 (0.99–1.00) 1.07 (1.03–1.12) 1.16 (1.06–1.27)
Europe (Ref ¼ 405 ng/mL)
Model 1 – 1.06 (0.90–1.25) 1.03 (0.93–1.14) 1.00 (1.00–1.00) 1.09 (1.02–1.15) 1.28 (1.18–1.40) –
Model 2 – 1.03 (0.87–1.22) 1.01 (0.91–1.13) 1.00 (1.00–1.00) 1.08 (1.02–1.15) 1.25 (1.15–1.36) –
Model 3 – 1.05 (0.89–1.25) 1.03 (0.92–1.15) 1.00 (1.00–1.00) 1.06 (0.99–1.12) 1.19 (1.08–1.30) –
Model 4 – 1.09 (0.92–1.30) 1.05 (0.94–1.18) 1.00 (1.00–1.00) 1.03 (0.97–1.09) 1.14 (1.04–1.25) –
Model 5 – 1.10 (0.93–1.31) 1.06 (0.95–1.18) 1.00 (1.00–1.00) 1.02 (0.96–1.09) 1.12 (1.02–1.23) –
Japan (Ref ¼ 83 ng/mL)
Model 1 1.00 (0.80–1.25) 1.00 (0.96–1.05) 1.06 (0.87–1.28) 1.27 (1.01–1.60) – – –
Model 2 0.97 (0.78–1.21) 1.01 (0.96–1.06) 1.07 (0.88–1.29) 1.23 (0.98–1.53) – – –
Model 3 1.04 (0.83–1.32) 0.99 (0.95–1.04) 1.00 (0.81–1.22) 1.12 (0.89–1.40) – – –
Model 4 1.07 (0.85–1.36) 0.99 (0.94–1.04) 0.97 (0.79–1.19) 1.07 (0.85–1.34) – – –
Model 5 1.06 (0.84–1.35) 0.99 (0.94–1.04) 0.98 (0.80–1.20) 1.07 (0.85–1.34) – – –
HR and 95% CIs of Figure 3A–C models at speciﬁed ferritin levels.
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region, all analyses were conducted separately for the USA,
Europe and Japan.
Patient characteristics by ferritin level
Table 2 shows that 8% of US patients had ferritin <200 ng/
mL; these patients tended to be younger, more likely male and
dialyzing with a catheter and had received larger ESA doses
than patients with ferritin 200 ng/mL. Forty-three percent of
US patients had ferritin 800 ng/mL and 16% had ferritin
1200ng/mL; patients with higher ferritin (800 ng/mL)
appeared to be older, with more years on dialysis (vintage),
higher WBC count and nPCR and lower hemoglobin levels and
were more likely to have received a bolus dose of IV iron than
patients with lower (<800 ng/mL) ferritin levels.
Table 3 shows that in Europe, 21% of patients had ferritin
<200 ng/mL, while 15% had ferritin 800 ng/mL, including
4% with ferritin 1200 ng/mL. Patients with ferritin <200 ng/
mL were younger and more likely male than those with ferritin
200 ng/mL. Patients with ferritin 800 ng/mL had higher
CRP and WBC count, were more likely to have recently re-
ceived a transfusion and had received higher IV iron doses than
patients with ferritin<800 ng/mL.
Table 4 shows that only 21% of Japanese patients had ferritin
200 ng/mL, while 34% had ferritin levels<50 ng/mL. Patients
Table 2. Patient characteristics by serum ferritin in US DOPPS (2009–15)
Patient characteristic All Serum ferritin (ng/mL)
<200 200–499 500–799 800–1199 1200
Patients, n (%) 8510 666 (8) 1910 (22) 2316 (27) 2261 (27) 1357 (16)
Demographics
Age (years), mean6 SD 62.46 15.1 59.16 15.9 60.76 15.1 62.26 14.8 63.4 6 14.9 65.16 14.8
Sex (male), % 56 63 60 56 53 51
Race (black), % 32 25 32 32 34 35
Vintage (years), mean6 SD 3.66 3.9 3.26 4.2 2.96 3.7 3.56 3.9 4.16 3.9 4.26 4.0
HD characteristics
Catheter use, % 28 39 38 28 22 22
Single pool Kt/V, mean6 SD 1.546 0.31 1.496 0.35 1.476 0.32 1.536 0.31 1.58 6 0.28 1.606 0.29
Anemia treatments (past 3–4 months)
IV iron (with any dose), % 77 64 82 80 77 72
IV iron (mg/week) among treated, mean6 SD 756 52 746 50 726 49 686 46 75 6 51 946 62
Bolusa dose of IV iron among treated, % 38 41 35 32 39 52
ESA (with any dose), % 93 84 93 94 93 94
ESA (1000 units/week) among treated, mean6 SD 156 15 226 20 166 15 156 14 13 6 14 146 15
Transfused, % – – – – – –
Anemia labs, mean6 SD
Ferritin (ng/mL) 7746 467 1196 54 3636 84 6506 86 9756 112 1, 5526 417
TSAT (%) 31.36 12.7 24.66 11.2 28.86 11.2 30.96 11.5 33.1 6 12.7 36.06 15.0
Hemoglobin (g/dL) 11.26 1.2 11.56 1.5 11.46 1.2 11.2 6 1.1 11.06 1.2 10.96 1.2
Nutrition and inﬂammation markers, mean6 SD
Body mass index (kg/m2) 28.76 7.0 28.96 6.6 28.96 7.0 28.8 6 7.2 28.76 7.1 28.06 6.8
Normalized PCR (g/kg/day) 0.956 0.26 0.916 0.26 0.936 0.26 0.956 0.26 0.97 6 0.25 0.976 0.26
Serum phosphorus (mg/dL) 5.26 1.5 5.36 1.5 5.26 1.5 5.26 1.5 5.16 1.4 5.16 1.5
Serum bicarbonate (mEq/L) 23.66 3.3 23.36 3.4 23.36 3.2 23.5 6 3.3 23.76 3.3 23.96 3.3
Serum potassium (mEq/L) 4.76 0.7 4.76 0.7 4.76 0.7 4.76 0.7 4.86 0.6 4.76 0.7
Serum creatinine (mg/dL) 8.26 3.1 8.16 3.2 8.26 3.1 8.26 3.1 8.36 2.9 8.26 3.1
Serum albumin (g/dL) 3.846 0.40 3.796 0.42 3.846 0.40 3.866 0.39 3.87 6 0.40 3.816 0.43
WBC count (1000 cells/mm3) 6.96 2.3 6.86 2.3 6.76 2.1 6.86 2.1 7.16 2.3 7.46 2.5
CRP (mg/L) – – – – – –
Hospitalized in past 3–4 months, % 16 19 17 14 15 19
Comorbid conditions, %
Coronary artery disease 32 32 31 33 31 30
Congestive heart failure 33 34 34 34 33 32
Cerebrovascular disease 10 9 9 9 10 11
Peripheral vascular disease 17 17 17 18 18 17
Other cardiovascular disease 17 19 16 17 16 17
Hypertension 81 84 80 80 82 82
Diabetes 61 56 62 63 62 58
Neurologic disease 7 8 7 7 7 8
Psychiatric disorder 13 17 12 13 12 13
Lung disease 11 13 12 11 11 11
Cancer (non-skin) 8 7 7 7 9 11
Gastrointestinal bleeding 3 3 3 3 3 4
Recurrent cellulitis, gangrene 8 8 9 8 8 5
Data on transfusions and CRP were not available in the USA.
aDeﬁned as at least 1month (of prior 3–4months) with IV iron dose 500mg.
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with very low ferritin (<50 ng/mL) had the highest levels of
phosphorus and creatinine. Patients with ferritin 200 ng/mL
(versus <200 ng/mL) tended to be older and were more likely
to have recently received IV iron—albeit still less likely (48%)
than in the USA and Europe, where more than three-quarters
of sampled patients received IV iron in the past 3–4months. In
each region, minimal differences in comorbidities were ob-
served across ferritin categories.
Trends in upper ferritin target levels
Figure 2 shows upper ferritin targets by region and calendar
year (2009–14) as reported by dialysis facility medical directors.
In the USA, the percentage of facilities with an upper ferritin tar-
get 1200ng/mL increased from 20% to 40% from 2010 to
2011. More than 90% of US facilities had an upper ferritin target
800ng/mL in 2014. While ferritin targets in Europe increased
from 2009 to 2014, upper targets of 500ng/mL remained com-
mon and no European facility had an upper ferritin target
1200ng/mL in 2014. In Japan, upper ferritin targets were even
lower, with most facilities targeting upper limits of300ng/mL.
Ferritin and mortality by level of adjustment
In the worldwide eligible sample of 18 261 patients,
1856 (10%) died within 1 year and 10 954 (60%) survived
Table 3. Patient characteristics by serum ferritin in Europe DOPPS (2009–15)
Patient characteristic All Serum ferritin (ng/mL)
<200 200–499 500–799 800
Patients, n (%) 6757 1443 (21) 2676 (40) 1636 (24) 1002 (15)
Demographics
Age (years), mean6 SD 65.96 14.9 64.66 15.0 66.16 15.2 66.86 14.5 65.8 6 14.6
Sex (male), % 62 68 62 60 55
Race (black), % 3 3 3 4 3
Vintage (years), mean6 SD 4.56 5.8 4.56 6.1 4.56 5.7 4.56 5.8 4.76 5.7
HD characteristics
Catheter use, % 28 31 28 28 27
Single pool Kt/V, mean6 SD 1.506 0.33 1.446 0.33 1.526 0.34 1.506 0.33 1.53 6 0.32
Anemia treatments (past 3–4 months)
IV iron (with any dose), % 79 73 81 81 77
IV iron (mg/week) among treated, mean6 SD 746 47 726 46 686 44 776 47 906 53
Bolusa dose of IV iron among treated, % 22 23 17 22 31
ESA (with any dose), % 90 84 91 93 93
ESA (1000 units/week) among treated, mean6 SD 106 8 116 9 106 8 9 6 8 9 6 8
Transfused, % 5 6 3 5 10
Anemia labs, mean6 SD
Ferritin (ng/mL) 4866 380 1166 54 3436 85 6286 85 1, 1666 438
TSAT (%) 28.06 12.5 22.76 10.6 27.26 10.7 29.96 12.4 35.1 6 15.3
Hemoglobin (g/dL) 11.56 1.4 11.6 6 1.5 11.5 6 1.3 11.4 6 1.3 11.36 1.4
Nutrition and inﬂammation markers, mean6 SD
Body mass index (kg/m2) 26.16 5.5 26.1 6 5.3 26.4 6 5.6 25.9 6 5.3 25.66 5.5
Normalized PCR (g/kg/day) 1.006 0.25 1.016 0.25 1.006 0.26 0.996 0.23 0.99 6 0.25
Serum phosphorus (mg/dL) 4.86 1.5 5.06 1.5 4.76 1.4 4.86 1.4 4.96 1.5
Serum bicarbonate (mEq/L) 23.26 3.3 22.7 6 3.4 23.2 6 3.2 23.2 6 3.3 23.56 3.5
Serum potassium (mEq/L) 5.06 0.8 5.16 0.8 5.06 0.8 5.06 0.8 5.16 0.9
Serum creatinine (mg/dL) 8.06 2.6 8.36 2.8 8.06 2.6 8.06 2.6 7.76 2.4
Serum albumin (g/dL) 3.726 0.47 3.736 0.47 3.726 0.46 3.686 0.48 3.72 6 0.48
WBC count (1000 cells/mm3) 7.06 2.2 7.06 2.2 7.06 2.3 7.06 2.2 7.36 2.3
CRP (mg/L), median (IQR) 6 (3–14) 5 (2–12) 5 (3–12) 6 (3–14) 8 (3–21)
Hospitalized in past 3–4 months, % 17 17 16 18 19
Comorbid conditions, %
Coronary artery disease 35 36 34 35 35
Congestive heart failure 19 17 19 18 20
Cerebrovascular disease 16 17 16 16 17
Peripheral vascular disease 30 34 30 28 30
Other cardiovascular disease 30 29 31 30 33
Hypertension 86 85 87 85 86
Diabetes 36 35 37 35 37
Neurologic disease 11 10 12 11 12
Psychiatric disorder 17 17 17 16 17
Lung disease 13 14 14 13 12
Cancer (nonskin) 17 15 16 19 19
Gastrointestinal bleeding 4 5 4 4 5
Recurrent cellulitis, gangrene 9 7 9 9 11
aDeﬁned as at least 1month (of prior 3–4months) with IV iron dose 500mg.
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1 year; among patients censored within 1 year, 501 (3%) re-
ceived a transplant, 109 (1%) changed modality to perito-
neal dialysis or home HD, 1164 (6%) transferred to
another facility, 3410 (19%) reached administrative study
phase end and 267 (1%) were otherwise lost to follow-up.
The crude all-cause mortality rate during the 1-year follow-
up period was 0.146/year (962 deaths) in the USA, 0.139/
year (757 deaths) in Europe and 0.051/year (137 deaths) in
Japan. Figures 3A–C illustrate the shape of the observed as-
sociation between ferritin and mortality by region and level
of covariate adjustment.
In the USA we observed a positive monotonic association
between ferritin and mortality after adjusting only for case mix,
Kt/V and catheter use (Figure 3A, Model 1). We observed rela-
tively small changes in the shape and magnitude of this associa-
tion after additional adjustment for IV iron dose, ESA dose and
hemoglobin (Model 2). Adjustment for nutrition, inflammation
and recent hospitalizations had a greater impact in attenuating
the association between high (versus median) ferritin and mor-
tality (Model 3).
In Europe we observed an elevated mortality rate at high lev-
els of ferritin in Figure 3B, Model 1, with minimal impact of
Table 4. Patient characteristics by serum ferritin in Japan DOPPS (2009–15)
Patient characteristic All Serum ferritin (ng/mL)
<50 50–99 100–199 200þ
Patients, n (%) 2994 1012 (34) 666 (22) 682 (23) 634 (21)
Demographics
Age (years), mean6 SD 64.96 12.0 63.86 11.8 64.56 12.5 65.6 6 11.7 66.26 12.1
Sex (male), % 66 67 65 65 66
Race (black), % 0 0 0 0 0
Vintage (years), mean6 SD 7.06 7.4 7.66 7.5 7.36 7.6 6.56 7.6 6.06 6.6
HD characteristics
Catheter use, % 1 0 2 1 2
Single pool Kt/V, mean6 SD 1.346 0.30 1.366 0.28 1.366 0.30 1.33 6 0.31 1.316 0.32
Anemia treatments (past 3–4 months)
IV iron (with any dose), % 33 21 32 39 48
IV iron (mg/week) among treated, mean6 SD 326 21 296 17 326 25 316 19 356 20
Bolusa dose of IV iron among treated, % 17 22 18 15 15
ESA (with any dose), % 90 83 90 94 95
ESA (1000 units/week) among treated, mean6 SD 6 6 5 6 6 5 56 4 5 6 4 6 6 5
Transfused, % 2 2 2 2 3
Anemia labs, mean6 SD
Ferritin (ng/mL) 1456 205 266 12 726 15 1416 29 4156 311
TSAT (%) 26.16 12.0 21.16 11.0 26.36 10.6 28.6 6 10.7 31.46 13.6
Hemoglobin (g/dL) 10.7 6 1.2 10.86 1.2 10.86 1.1 10.76 1.1 10.4 6 1.3
Nutrition and inﬂammation markers, mean6 SD
Body mass index (kg/m2) 21.5 6 3.5 21.86 3.5 21.56 3.7 21.46 3.4 21.0 6 3.1
Normalized PCR (g/kg/day) 0.926 0.21 0.936 0.19 0.926 0.21 0.92 6 0.22 0.926 0.22
Serum phosphorus (mg/dL) 5.36 1.3 5.56 1.3 5.36 1.3 5.16 1.3 5.26 1.3
Serum bicarbonate (mEq/L) – – – – –
Serum potassium (mEq/L) 4.86 0.8 4.96 0.7 4.86 0.8 4.86 0.8 4.86 0.8
Serum creatinine (mg/dL) 10.4 6 2.9 10.96 3.0 10.46 2.8 10.16 2.8 9.96 3.0
Serum albumin (g/dL) 3.706 0.41 3.716 0.40 3.706 0.40 3.72 6 0.39 3.676 0.45
WBC count (1000 cells/mm3) 5.96 1.9 6.06 1.9 5.86 1.9 5.86 1.9 5.96 2.0
CRP (mg/L), median (IQR) 1 (1–3) 1 (1–3) 1 (0–3) 1 (0–3) 1 (1–5)
Hospitalized in past 3–4 months, % 10 10 9 9 11
Comorbid conditions, %
Coronary artery disease 27 26 28 27 29
Congestive heart failure 19 19 17 20 19
Cerebrovascular disease 12 12 12 12 14
Peripheral vascular disease 16 16 17 18 14
Other cardiovascular disease 25 24 26 24 26
Hypertension 80 78 80 80 85
Diabetes 40 41 38 40 38
Neurologic disease 7 5 7 8 7
Psychiatric disorder 5 5 5 5 6
Lung disease 4 3 4 3 5
Cancer (nonskin) 11 10 9 11 14
Gastrointestinal bleeding 5 6 4 3 5
Recurrent cellulitis, gangrene 4 4 4 3 4
Serum bicarbonate was not measured in 80% of Japanese patients.
aDeﬁned as at least 1month (of prior 3–4months) with IV iron dose 500mg.
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adjustment for anemia factors (Model 2). Adjustment for recent
hospitalization and markers of nutrition and inflammation
(Model 3), particularly CRP (Model 4), attenuated this associa-
tion between high (versus median) ferritin and mortality.
Further adjustment for blood transfusions had minimal impact
(Model 5). Regarding low versus median ferritin, Models 3 and
4 adjustments pushed the HR slightly >1, resulting in a weak
J-shaped association.
In Japan we observed a positive monotonic association be-
tween ferritin and mortality in Figure 3C, Model 1, again with
minimal impact on adjusting for anemia factors (Model 2).
Similar to Europe, adjustment for recent hospitalization, nutri-
tion and inflammation (including CRP) resulted in attenuation
of the high (versus median) ferritin and mortality association
and a weak J-shape with slightly elevated mortality at the lowest
ferritin levels (Model 5).
DISCUSSION
In this international study of >18 000 HD patients, we
observed that both facility ferritin targets and patient ferritin
levels were highest in the USA, followed by Europe and Japan.
Relatively high ferritin levels in each region were associated
with higher mortality rates in a model minimally adjusted for
case mix. In each region, adjustment for markers of nutrition
and inflammation (Model 3), particularly for CRP in Europe
and Japan (Model 4), attenuated this association more than
adjustment for anemia measures and treatments (Model 2).
After adjustment for all measured confounders, the ferritin–
mortality association was positive monotonic in the USA and
somewhat J-shaped in Europe (nadir 500 ng/mL) and Japan
(nadir 175 ng/mL), where patients with the lowest ferritin
levels had slightly higher (10%) mortality rates compared
with the region-specific medians.
While nutrition, inflammation and recent prior hospitaliza-
tion appear to play a large role in explaining the ferritin–
mortality relation, it was not to the degree observed by
Kalantar-Zadeh et al. [8]. Discrepancies between that study [8],
using a 2001–03 cohort, and our US results may be due in part
to differences in anemia management practices across time, pa-
tient mix, exposure measurement (baseline versus time-varying
ferritin) and/or covariate adjustment.
In our European cohort, the positive monotonic association
between ferritin and mortality at ferritin levels >500 ng/mL
was comparable to our US results at the same levels of adjust-
ment. Because adjustment for CRP and blood transfusions (not
available in US data) further attenuated this association, we
speculate that the observed ferritin–mortality relation in the
USA may be exaggerated by our inability to more fully account
for inflammation as in Europe and Japan, with the true associa-
tion likely flatter than that shown in Figure 3A, Model 3.
Three recent multicenter studies of Japanese HD patients
have explored the association between ferritin and mortality
[40–42]. Maruyama et al. [40] found an elevated mortality rate
only among HD patients in their highest decile of serum ferritin
(>496 ng/mL). Kuragano et al. [41] found a higher rate of infec-
tion and cerebrocardiovascular disease (but not all-cause mor-
tality) among patients with high ferritin; however, because high
ferritin was defined as>100 ng/mL, the observed elevated mor-
tality rate may have been driven by patients with ferritin levels
far exceeding 100 ng/mL. A recent analysis of Japan DOPPS
data focused on effect modification of the ferritin–mortality as-
sociation by markers of inflammation [42]. The results showed
a U-shaped association between ferritin and all-cause mortality,
with the 50–99 ng/mL ferritin group having the best survival,
but only among noninflamed patients. Our findings showed the
lowest adjusted mortality rate was at 100–250 ng/mL, though
precision was low in Japan due to fewer events.
To bolster hemoglobin levels while avoiding the potential
risk (and often higher cost) of high ESA doses, many HD facili-
ties have increased IV iron dosing, often in the form of a bolus
dose spread over 5–10 HD sessions or a single, large-dose iron
FIGURE 2: Trend in facility upper ferritin target, by year (Medical Director Survey data, 2009–14). Results were rounded to the ﬁve most com-
mon upper target values.
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FIGURE 3: Association of ferritin level with mortality, shown by progressive adjustment in (A) USA, (B) Europe and (C) Japan (reference
point ¼ region-speciﬁc median). Restricted cubic splines with three knots used to model ferritin and mortality in Cox regression models, strati-
ﬁed by calendar year and by large dialysis organization in the USA or by country in Europe. Results outside of cohort-speciﬁc 5th and 95th per-
centiles were suppressed to limit tenuous extrapolation. Adjustments in Model 1 (case mix): age, sex, black race, vintage, 13 comorbidities,
catheter use and Kt/V at study entry; Model 2 (anemia factors): Model 1 plus hemoglobin, average IV iron and ESA dose prescribed during the
3–4months prior to ferritin measurement, an interaction between IV iron dose and vintage and an indicator for whether the patient received a
bolus IV iron dose, deﬁned as at least 1 of the 3–4 prior months with at least 500mg IV iron; Model 3 (nutrition and inﬂammation): Model 2
plus BMI and nPCR at study entry, any hospitalization during the prior 3–4months, albumin, creatinine, WBC count, potassium, bicarbonate,
phosphorus and phosphorus squared; Model 4: Model 3 plus CRP (not measured routinely in the USA); Model 5: Model 4 plus indicator for
any blood transfusion in the prior 3–4months (only limited data collected in USA). Table 1 provides CIs for all models in panels A–C at se-
lected ferritin increments.
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preparation [43], raising the question of whether ESA toxicity is
being replaced with iron toxicity [44]. Results of large multicen-
ter studies of the effect of IV iron dosing onmortality have been
mixed [7–11], and the ongoing Proactive IV irOn Therapy in
haemodiALysis patients (PIVOTAL) clinical trial in the UK
[45] compares clinical outcomes among dialysis patients
assigned to higher-versus lower-dose IV iron regimens. If an IV
iron effect on mortality exists, we would expect that the associa-
tion between high ferritin levels, a marker of iron stores, and ad-
verse events would be confounded by a high IV iron dose.
However, we observed a minimal impact of adjustment for ane-
mia management parameters on the ferritin–mortality associa-
tion, suggesting that any effect of high IV iron dose on survival
may be minimally related to body iron stores. Alternatively, se-
rum ferritin may be an exceedingly poor marker of body iron
stores in common clinical practice, particularly when only mea-
sured every 3months. As others have suggested, the utility of
high ferritin as a biomarker of any one particular condition
may be limited [13–17, 22, 23]. Because ferritin levels are af-
fected by a variety of clinical conditions and treatments, it is
perhaps not surprising to observe differential associations with
mortality across regions where the prevalence of these condi-
tions and treatments vary widely.
A limitation of this study is that inflammation cannot be di-
rectly observed. We relied on proxy variables such as serum al-
bumin, WBC count and CRP, which in combination may not
fully reflect a patient’s inflammation status. Results may also be
biased by other unmeasured confounders. Although this bias
may be greatest in the USA, where transfusions and CRP data
are missing, the impact of these variables observed in other
regions can provide an approximation of what we might expect
to observe in the USA. Another potential unmeasured con-
founder is cumulative IV iron dose on dialysis, which is unavail-
able for the majority of DOPPS patients due to the lack of data
on IV iron dosing before DOPPS enrollment. If the impact of
IV iron dosing is related more to cumulative than short-term
exposure, then the effect may not be well captured in our 3- to
4-month window of observation. To help alleviate this potential
bias, we adjusted for dialysis vintage, a strong correlate of cumu-
lative IV iron dose, and the interaction between IV iron dose
and vintage. Finally, a limitation of analyzing a single ferritin
value for each patient is the potential for misclassification due to
the high degree of within-patient variability of ferritin levels [22,
23]. This misclassification is most likely nondifferential, which
would probably lead to misclassification bias toward the null.
To our knowledge, we are the first to explore the ferritin–mor-
tality relation in the postbundle [27] era when ferritin levels
>800ng/mL are common in the USA. In total, >90% of US
DOPPS facilities—and>50% of European DOPPS facilities—had
upper ferritin targets exceeding the KDIGO guideline of 500ng/
mL. Other strengths of our study include a large sample size, inter-
national data collected with a standardized protocol, careful con-
sideration of potential confounders and use of restricted cubic
splines to explore the functional form of the ferritin–mortality as-
sociationmore accurately and precisely than prior publications.
In this study, high ferritin level was consistently associated
with elevated mortality in each region in minimally adjusted
models. While both inflammation and anemia management
practices affect ferritin levels, the association between high ferri-
tin and mortality was attenuated more by adjustment for
markers of malnutrition and inflammation than by hemoglobin
levels, IV iron and ESA doses. The residual associations between
high ferritin and mortality may reflect effects of inflammation or
iron not explained by measured variables. High serum ferritin is
often used to limit iron repletion therapy, based on safety con-
cerns [3], but our results suggest that the utility of high ferritin as
a biomarker for clinical risk due to excess iron stores is limited.
However, based on the positive ferritin–mortality association
remaining after adjustment, caution regarding IV iron dosing to
higher upper ferritin targets may remain warranted. Research to
resolve criteria for iron dosing, and whether optimal anemia
management strategies differ internationally, is still needed.
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